7th-Jan-2020: The global opioid use
disorder market size is expected to reach USD 4.5 billion
by 2026, according to a new report by Grand View Research, Inc., exhibiting a
CAGR of 10.1% over the forecast period. Rising opioid epidemic and growing
government initiatives to combat the crisis are likely to propel market growth.
In addition, growing commercialization of novel products is further anticipated
to drive growth. In 2018, about 2.9 million people aged 15 or above were
suffering from this disorder in the U.S. In 2016, according to the National
Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people
had abused prescription opioids in the earlier year and more than 2 million
were addicted to prescribed drugs.
According to the
CDC, around 130 Americans die every day due to the opioid overdose and the U.S.
government has designated this as a public health emergency.For patients
wanting to overcome their addiction, adherence to a Medication-assisted
Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by
half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and
naltrexone. They are available in numerous dosages and formulations, with daily
oral buprenorphine as the standard of care.
To combat the
opioid crisis, several measures have been undertaken in recent years. For
instance, in 2016, CDC clinical practice guidelines for prescribing these drugs
for chronic pain were issued and new American Society of Addiction Medicine (ASAM)
National Practice Guidelines was adopted in 2015 to improve standard of care.
Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations
for abuse-deterrent opioids, enhance safety labeling, and re-examine the
risk-benefit paradigm of their use.
In
depth research report on Opioid Use Disorder Market
Further key findings from the report suggest:
·
Buprenorphine was the largest revenue generating segment in
2018. Its sublingual tablets and branded drug Suboxone are the most widely
prescribed drug for OUD
·
Suboxone is the highest prescribed drug in the OUD market,
mostly due to its excellent clinical profile
·
Sublocade, a buprenorphine product, is estimated to be the
largest and fastest growing product over the forecast period, as it is the
first long-acting buprenorphine and the first once-monthly product
·
North America generated the highest revenue in 2018, followed
by Europe
·
Some of the major players in the opioid use disorder market
include are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals,
Teva Pharmaceuticals, MediciNova, Orexo, Camurus, and Omeros
·
The key players are adopting strategies such as mergers and acquisitions,
product development, product extension, and regional expansion to increase
their market share
·
In 2018, Orexo AB announced that it obtained the rights to
commercialize Zubsolv in all the territories outside the U.S. from its current
partner Mundipharma
Grand View Research has segmented the opioid use disorder
market on the basis of drug and region:
Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2015
- 2026)
·
Buprenorphine
·
Bunavail
·
Sublocade
·
Suboxone
·
Zubsolv
·
Others
·
Methadone
·
Naltrexone
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is the
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment